NCT06795191View on ClinicalTrials.gov

Efficacy, Safety, and Pharmacokinetics of FP-014, 22.5 mg in Patients With Advanced Prostate Cancer

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 1, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

January 2, 2028

Conditions
Prostate Cancer
Interventions
DRUG

Triptorelin Mesylate

22.5 mg in a prefilled, ready-to-use, long-acting formulation

Sponsors
All Listed Sponsors
collaborator

QPS Holdings LLC

INDUSTRY

lead

Foresee Pharmaceuticals Co., Ltd.

INDUSTRY